European CHMP recommends approval of use of perampanel in younger patients

The CHMP has recommended the approval of its use from age 4 years for the partial-onset seizures indication and from 7 years for the primary generalised tonic-clonic indication (currently both are from 12 years). Final approval is awaited.


European Medicines Agency